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Whole blood microRNA levels 
associate with glycemic status 
and correlate with target mRNAs 
in pathways important to type 2 
diabetes
Nina Mononen1, Leo-pekka Lyytikäinen  1, Ilkka seppälä  1, pashupati p. Mishra1, 
Markus Juonala2, Melanie Waldenberger3, Norman Klopp4,5, thomas Illig3,4,5, Jaana Leiviskä6, 
Britt-Marie Loo7, Reijo Laaksonen1, Niku oksala1,8, Mika Kähönen9, Nina Hutri-Kähönen10, 
olli Raitakari11,12, terho Lehtimäki1 & emma Raitoharju1
We analyzed the associations between whole blood microRNA profiles and the indices of glucose 
metabolism and impaired fasting glucose and examined whether the discovered microRNAs correlate 
with the expression of their mRNA targets. MicroRNA and gene expression profiling were performed 
for the Young Finns Study participants (n = 871). Glucose, insulin, and glycated hemoglobin (HbA1c) 
levels were measured, the insulin resistance index (HOMA2-IR) was calculated, and the glycemic status 
(normoglycemic [n = 534]/impaired fasting glucose [IFG] [n = 252]/type 2 diabetes [T2D] [n = 24]) 
determined. Levels of hsa-miR-144-5p, -122-5p, -148a-3p, -589-5p, and hsa-let-7a-5p associated with 
glycemic status. hsa-miR-144-5p and -148a-3p associated with glucose levels, while hsa-miR-144-5p, 
-122-5p, -184, and -339-3p associated with insulin levels and HOMA2-IR, and hsa-miR-148a-3p, -15b-
3p, -93-3p, -146b-5p, -221-3p, -18a-3p, -642a-5p, and -181-2-3p associated with HbA1c levels. The 
targets of hsa-miR-146b-5p that correlated with its levels were enriched in inflammatory pathways, and 
the targets of hsa-miR-221-3p were enriched in insulin signaling and T2D pathways. These pathways 
showed indications of co-regulation by HbA1c-associated miRNAs. There were significant differences 
in the microRNA profiles associated with glucose, insulin, or HOMA-IR compared to those associated 
with HbA1c. The HbA1c-associated miRNAs also correlated with the expression of target mRNAs in 
pathways important to the development of T2D.
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Globally, approximately 422 million adults were living with diabetes in 2014, and the age-standardized prevalence 
has more than doubled since 19801. The majority of the cases of diabetes in adults are of type 2 (T2D), and in 
addition to increasing rates in adults, T2D accounts for 8–45% of all new cases of diabetes reported among chil-
dren and adolescents2. The development of T2D is asymptomatic, and disease that already fulfils the diagnostic 
criteria of T2D often remains subclinical for a long period. Prior to T2D, individuals can reside in the high-risk 
state of prediabetes, defined as impaired fasting glucose (IFG) or impaired glucose tolerance3.
T2D is a complex multi-organ disease with many interrelated dysfunctions. Insulin resistance in the skeletal 
muscles and in adipose tissue is followed initially by an increase in insulin production in pancreatic β-cells. The 
failure to respond to the increased insulin demand will eventually lead to progressive β-cell failure, hyperglyce-
mia, and glucose toxicity. The disease is also characterized by the accumulation of fat in the liver, as adipose tissue 
lipolysis is not sufficiently inhibited by insulin in type 2 diabetes. The pathogenesis of T2D has been shown to 
be heterogenic, and the progression of the disease, for example, differs according to the age of onset4. The risk of 
complications also varies according to ethnicity5 as well as the level of control of the glycemic status6.
The rise in the prevalence of T2D is tied to the increasing rates of obesity. Positive T2D family history also 
increases the risk for developing the disease7, even though independent variations in the DNA code have been 
shown to explain only a small proportion of the heritability of T2D8,9. Recently, it has been hypothesized that the 
effect could also be conveyed by epigenetic changes and that these changes could be mediated by predisposing 
individuals to the risk of insulin resistance during gestation, and possibly even by the inter- and transgenerational 
transmission of the disorder7.
MicroRNAs (miRNAs, miRs) are small non-protein coding RNAs. They are known to regulate gene expres-
sion at the post-transcriptional level by binding to target mRNAs and affecting their translation. MicroRNAs can 
control several genes, and individual mRNAs can be bound by several miRNAs—miRNAs can thus establish wide 
regulatory networks affecting several metabolic processes. Research on T2D and miRNAs in humans has focused 
on the identification of possible biomarkers for established T2D. The results have been inconsistent, mainly due 
to the small populations studied, different starting materials and profiling methods, preselected pools of miRNAs, 
and the heterogeneity of T2D as a disease10. A meta-analysis by Zhu et al. indicated that miR-29a, -34a, -375, -103, 
-107, -132, -142-3p, and -144 could be potential circulatory biomarkers (plasma, serum, peripheral blood mon-
onuclear cells, and whole blood as profiling samples) for T2D10, while another meta-analysis reported that levels 
of miR-320a, -142-3p, -222, -29a, -27a, and -375 increased and levels of miR-197, -20b, -17, and -652 decreased 
in individuals with T2D11.
In contrast to these studies, more long-term solutions for the T2D epidemic could be reached by identifying 
individuals early in the prediabetic state and by understanding the function of miRNAs in both the normoglyce-
mic (NG) and prediabetic state. However, miRNAs in prediabetes have been studied far less. Villard et al. showed 
that only circulatory miR-29a, -192, and -126 were consistently dysregulated in individuals with prediabetes11. 
Although we have seen interesting results—indicating, for example, changes in serum miR-192, -193b12 and -126 
in response to glycemic status and intervention—most studies in humans on miRNAs and prediabetes have been 
small case/control studies (n < 100)12–17 or/and no multiple testing correction has been utilized12–14,18, and/or they 
were performed with only preselected miRNAs14,17–19.
The aims of this study were to (i) analyze the difference in the whole blood miRNA expression in indi-
viduals with and without IFG in the large (n = 871; individuals with IFG = 252 and those with T2D = 24) 
population-based Young Finns Study (YFS) cohort (aged 34–49 years) with individuals currently approaching 
the age when T2D is most frequently diagnosed; (ii) to study the association of glucose, insulin, and glycated 
hemoglobin (HbA1c) levels with the HOMA2 insulin resistance (HOMA-IR) index and whole blood miRNA 
levels; (iii) to look for insight into the cellular origins of the miRNAs of interest by correlating their levels with the 
blood cell counts; (iv) to investigate whether these miRNAs of interest correlate with their predicted targets and 
whether the correlated targets are enriched in specific biological pathways; and (v) to see whether the miRNAs of 
interest together may co-regulate these pathways.
Results
The levels of five miRNAs are associated with glycemic status. The Kruskal-Wallis test on glycemic 
status groups (NG, IFG, and T2D) showed a significant association (pc < 0.05) for the levels of hsa-miR-144-5p, 
-122-5p, -148a-3p, -589-5p, and hsa-let7a-5p. Hsa-miR-144-5p and hsa-let7a-5p were significantly down-reg-
ulated in individuals with IFG (vs. NG) (pc < 0.05, FC = 0.91 and FC = 0.93, respectively) (Fig. 1A, Table 1, 
Supplementary Table S1). Both of the miRNAs were significant (p < 0.05) statistical predictors of IFG (vs. NG) 
also in the fully adjusted model 2. Hsa-miR-148a-3p was also down-regulated in individuals with IFG (FC = 0.92) 
and up-regulated in those with T2D (vs. NG) (FC = 1.12) (Fig. 1A), but the significance did not survive multiple 
testing correction and this miRNA was thus not included in further regression analysis.
When comparing T2D individuals with NG individuals, hsa-miR-122-5p and hsa-miR-589-3p were 
up-regulated (pc < 0.05, FC = 1.53 and FC = 1.29, respectively) (Fig. 1B, Table 1, Supplementary Table S1). Both 
of these miRNAs were also up-regulated (p < 0.05 but pc > 0.05) in T2D, in comparison to individuals with IFG 
(FC = 1.34 and FC = 1.32). Hsa-miR-589-3p was an independent statistical predictor of T2D when compared to 
NG or IFG individuals in fully adjusted model 2, and hsa-miR-122-5p was an independent statistical predictor of 
T2D when compared to NG individuals also in the fully adjusted model, but not when compared to individuals 
with IFG (Fig. 1A, Table 1, Supplementary Table S1).
Twelve miRNAs significantly associate with glucose and HbA1c levels and/or indicators of 
insulin resistance. In addition to being down-regulated in individuals with prediabetes, hsa-miR-144-5p 
also correlated inversely (pc < 0.05) with insulin levels and the HOMA2 index. This miRNA also associated with 
serum glucose levels in the fully adjusted model 2 (p < 0.05), but adding triglycerides to the model predicting 
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insulin and HOMA2 index levels abolished the association. Further analysis showed that this miRNA corre-
lated even more significantly with serum triglyceride levels (p = 7.3*10−20, r = −0.304). Only one other miRNA 
(hsa-miR-148a-3p) correlated with serum glucose levels and also associated with serum glucose levels in the fully 
adjusted model 2 (Table 2, Supplementary Table S2).
Hsa-miR-122-5p, -184, and -339-3p correlated with insulin levels and HOMA2 index (pc < 0.05). Hsa-miR-
122-5p, which was also up-regulated in individuals with T2D, is the only miRNA with a direct correlation with 
these indicators of insulin resistance. Unlike hsa-miR-144-5p, these three miRNAs have an independent asso-
ciation with insulin levels and HOMA2 index in the fully adjusted model (p < 0.05) (Table 2, Supplementary 
Table S2).
Hsa-miR-144-5p, -148a-3p, -15b-3p, -93-3p, -146b-5p, -221-3p, -642a-5p, -181a-2-3p, and -18a-3p correlated 
with either HbA1c and/or HbA1c% (pc < 0.05). Hsa-miR-148a-3p, -15-3p, -93-5p, and -18-3p had an inverse 
Figure 1. Blood levels of hsa-miR-144- 5p, -let-7a-5p (A), -122-5p, -589-3p, and -148a-3p (B) in 
normoglycemic individuals (NG), individuals with impaired fasting glucose (IFG) and individuals with type 2 
diabetes (T2D). The trend over groups is analyzed using the Kruskal-Wallis test (dash line) and the differences 
between groups by the Mann-Whitney U test (solid line). Hsa-miR-144-5p and Let-7a-5p are significantly 
(Bonferroni corrected p < 0.05) down-regulated in IFG vs. NG (A), while hsa-miR-122-5p and 589-3p were 
significantly up-regulated in T2D vs. NG (B).
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correlation with HbA1c/HbA1c%, while the other miRNAs had a positive correlation with their levels. All except 
hsa-miR-144-5p associated significantly with the levels of HbA1c/HbA1c% in the fully adjusted model (Table 2, 
Supplementary Table S3).
Distinct miRNAs are associated with indicators of glucose levels and insulin resistance in NG 
and IFG individuals. In NG individuals, significant (pc < 0.05) correlations were seen only between miRNA 
levels and levels of HbA1c or HbA1c%. Hsa-miR-221-3p and -642a-5p, which were associated with HbA1c and 
HbA1c% in the whole population, had a positive correlation with these variables, and these miRNAs had an inde-
pendent association with HbA1c levels and percentages in the fully adjusted model as well. In addition, hsa-miR-
589-3p, which was up-regulated in individuals with T2D, correlated negatively with HbA1c and HbA1c% and 
also associated with these values in the fully adjusted model. In individuals with IFG, hsa-miR-589-3p was not 
associated with HbA1c and HbA1c% levels, and in individuals with T2D (n = 24), the correlation was positive 
(p = 0.032, r = 0.438 and p = 0.034, r = 0.435 respectively), but this did not survive multiple testing correction 
(pc > 0.05). Hsa-miR-454-5p had a correlation (pc < 0.05) only with HbA1c%, even though it was associated with 
both HbA1c and HbA1c% (pc < 0.05) in the fully adjusted model (Table 3 and Supplementary Tables S4 and S5).
In individuals with IFG, hsa-miR-122-5p and -146b-5p showed association patterns similar to their patterns 
in the whole population, with hsa-miR-122-5p levels having an independent association with insulin levels 
and HOMA2 index, while hsa-miR-146b-5p associated with the levels of HbA1c and HbA1c%. Furthermore, 
hsa-miR-885-5p and -106b-5p correlated positively with serum glucose levels and also had an independent asso-
ciation with glucose levels in the fully adjusted model in individuals with IFG (Table 3, Supplementary Tables S4 
and S5).
Expression patterns and technical validation of data. No clear expression clusters were identified 
when analyzing the miRNAs of interest. We could see an increased amount of significant positive correlations 
between miRNAs that associated with insulin levels/HOMA2-IR index and, similarly, between those that associ-
ated with HbA1c and HbA1c% levels, but the most significant correlations were the negative associations between 
hsa-miR-221-3p, and hsa-miR-589-3p and hsa-miR-18a-3p (Supplementary Fig. S3).
The functionality of the miRNA profiling arrays has been previously validated in a smaller sample popu-
lation (n = 72) by correlating the results obtained by this method with those achieved with Human MiRNA 
Microarray Release 14.0, 8 × 15 K (Agilent). The correlation between the methods was good, and the association 
between hsa-miR-144-5p and serum glucose levels, for example, was also seen in the results obtained with the 
Agilent array20. To further validate the results, we detected a similar pattern in the expressions of hsa-miR-144-5p 
and -let-7a between the glycemic status groups (Supplementary Fig. S1) and even succeeded in replicating the 
IFG vs. NG T2D vs. NG T2D vs. IFG
p-value
FC/
OR p-value
FC/
OR p-value
FC/
OR
hsa-miR-144-5p
U-test 2.35*10−6 0.91 0.033 0.90
Model 1 7.42*10−5 0.71 0.043 0.63
Model 2 3.64*10−4 0.73
hsa-let-7a-5p
U-test 6.39*10−6 0.93
Model 1 3.00*10−4 0.74
Model 2 4.50*10−4 0.73
hsa-miR-122-5p
U-test 0.006 1.14 4.80*10−5 1.53 0.009 1.34
Model 1 0.002 2.68 0.042 1.64
Model 2 0.010 2.48
hsa-miR-589-3p
U-test 1.82*10−4 1.29 6.60*10−5 1.32
Model 1 2.34*10−4 2.53 2.27*10−4 2.51
Model 2 3.70*10−4 2.80 1.65*10−4 2.83
Table 1. Significant (pc < 0.05) associations between miRNAs and individuals’ glycemic status (normoglycemic 
[NG/impaired fasting glucose [IFG]/type 2 diabetes [T2D]). Associations are evaluated with the Mann-
Whitney U test and stepwise logistic regression models. Only p-values smaller than 0.05 are shown here and 
those with a pc < 0.05 are indicated by bold font. *Multiply sign. Fold changes (FC) describe the magnitude 
of the difference with the Mann-Whitney U test, while odds ratios (OR) were calculated with regression 
models. All p-values, numbers of samples, and 95% CIs are shown in Supplementary Table 1. Statistical model: 
U-test = Mann-Whitney U test; Model 1 = stepwise logistic regression model including miRNA of interest (one 
by one), age, sex, and BMI; Model 2 = Model 1 + leukocyte, erythrocyte, and thrombocyte count, in addition to 
total cholesterol, LDL, HDL, and triglyceride levels, as well as alcohol consumption, and history of smoking or 
hypertension.
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Glucose Insulin HOMA2-IR HbA1c HbA1c %
p-value r/β p-value r/β p-value r/β p-value r/β p-value r/β
hsa-miR-144-5p
Correlation 7.67*10−7 −0.167 1.35*10−8 −0.192 1.81*10−8 −0.190 8.05*10−5 −0.134 5.80*10−5 −0.137
Model 1 1.57*10−7 −0.163 8.19*10−5 −0.113 9.99*10−5 −0.111 0.009 −0.086 0.009 −0.084
Model 2 1.22*10−5 −0.14
hsa-miR-148a-3p
Correlation 1.71*10−4 −0.136 0.033 −0.078 0.023 −0.083 1.39*10−5 −0.158 9.39*10−6 −0.161
Model 1 0.002 −0.103 7.72*10−5 −0.135 6.00*10−5 −0.137
Model 2 0.015 −0.082 5.05*10−5 −0.14 3.74*10−5 −0.143
hsa-miR-122-5p
Correlation 3.17*10−4 0.135 1.49*10−11 0.251 7.37*10−12 0.255 3.58*10−4 0.134 2.23*10−4 0.139
Model 1 1.52*10−4 0.119 6.41*10−5 0.124 0.004 0.105 0.004 0.107
Model 2 2.48*10−4 0.109 2.09*10−4 0.110 0.005 0.104 0.005 0.104
hsa-miR-184
Correlation 0.002 −0.108 2.86*10−5 −0.145 1.03*10−5 −0.153
Model 1 0.001 −0.099 1.76*10−4 −0.109
Model 2 0.007 −0.088 0.004 −0.08 0.003 −0.084
hsa-miR-339-3p
Correlation 4.44*10−5 −0.140 4.66*10−5 −0.139
Model 1 0.001 −0.094 0.001 −0.095
Model 2 0.006 −0.077 0.003 −0.083
hsa-miR-15b-3p
Correlation 0.006 −0.099 0.008 −0.096 0.001 −0.121 1.27*10−4 −0.139
Model 1 0.003 −0.089 0.007 −0.082 1.80*10−4 −0.128 5.55*10−5 −0.138
Model 2 0.031 −0.075
hsa-miR-93-3p
Correlation 0.045 −0.068 3.29*10−6 −0.157 5.78*10−6 −0.153
Model 1 0.036 −0.060 0.019 −0.066 8.73*10−7 −0.157 1.11*10−6 −0.155
Model 2 8.21*10−6 −0.145 1.06*10−5 −0.143
hsa-miR-146b-5p
Correlation 0.011 0.086 0.014 0.084 3.32*10−6 0.157 2.39*10−6 0.159
Model 1 9.57*10−5 0.126 9.39*10−5 0.126
Model 2 8.05*10−5 0.123 2.58*10−4 0.122
hsa-miR-221-3p
Correlation 0.013 0.085 0.015 0.082 9.62*10−5 0.132 2.74*10−4 0.123
Model 1 1.82*10−4 0.120 0.001 0.109
Model 2 0.006 0.095 0.014 0.085
hsa-miR-642a-5p
Correlation 4.51*10−7 0.170 7.95*10−7 0.167
Model 1 8.46*10−8 0.171 1.73*10−7 0.167
Model 2 8.70*10−8 0.176 1.54*10−7 0.173
hsa-miR-181a-2-3p
Correlation 2.50*10−5 0.143 2.92*10−5 0.142
Model 1 1.62*10−4 0.121 2.10*10−4 0.119
Model 2 0.001 0.110 0.001 0.106
hsa-miR-18a-3p
Correlation 1.30*10−4 −0.130 1.18*10−4 −0.131
Model 1 0.001 −0.109 0.001 −0.106
Model 2 0.002 −0.104 0.002 −0.102
Table 2. Significant (pc < 0.05) associations between miRNAs and serum glucose and insulin levels, the 
HOMA2 insulin resistance index, and glycated hemoglobin (HbA1c) levels and percentage. Associations are 
evaluated with Spearman’s correlation and stepwise linear regression models. *Multiply sign. Only p-values 
smaller than 0.05 are shown here, and those with a pc < 0.05 are indicated by bold font. All p-values, numbers 
of samples, and 95% CIs are shown in Supplementary Tables 2 and 3. Statistical model: Correlation = Spearman 
correlation; Model 1 = Stepwise regression model including miRNA of interest (one by one), age, sex, and BMI; 
Model = Model 1 + leukocyte, erythrocyte, and thrombocyte count, in addition to total cholesterol, LDL, HDL, 
and triglyceride levels, as well as glycemic status, alcohol consumption, and history of smoking or hypertension.
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nominally significant difference between NG and IFG groups in has-let-7a levels (p = 0.003, FC = 0.97) and the 
borderline significant result in hsa-miR-144-5p levels (p = 0.061, FC = 0.91) in the same setting.
MicroRNAs hsa-miR-146b-5p, -221-3p and -589-3p associated with blood cell counts, while 
only hsa-miR-122-5p levels are originated solely from serum. To analyze the possibility that the 
miRNAs that were associated with the individuals’ glycemic status, glucose levels, or indicators of insulin resist-
ance are expressed particularly in certain circulatory blood cells, we correlated the levels of these miRNAs with 
the leukocyte, erythrocyte, and thrombocyte counts. Out of the 16 miRNAs, hsa-miR-146b-5p and -589-3p 
correlated significantly with the leukocyte count (p = 1.01*10−4, r = 0.132 and p = 7.20*10−5, r = −0.135), and 
hsa-miR-589-3p hd an even stronger negative correlation with the erythrocyte count (p = 4.85*10−6, r = −0.155). 
Also, hsa-miR-106b-5p levels correlated with the leukocyte count in the whole population (p = 2.60*10−5, 
r = −0.143), but no association was seen in the subpopulation of individuals with IFG, where hsa-miR-106b-5p 
associated with glucose levels. Only levels of hsa-miR-221-3p correlated significantly with the thrombocyte count 
(p = 1.58*10−18, r = 0.293).
Serum glucose Insulin HOMA2-IR HbA1c HbA1c %
p-value r/β p-value r/β p-value r/β p-value r/β p-value r/β
In normoglycemic individuals
hsa-miR-589-3p
Correlation 0.007 −0.117 0.007 −0.117 1.80*10−5 −0.185 4.80*10−5 −0.175
Model 1 0.045 −0.077 0.049 −0.075 4.61*10−5 −0.167 1.37*10−4 −0.154
Model 2 1.03*10−4 −0.158 2.68*10−4 −0.147
hsa-miR-221-3p
Correlation 4.50*10−5 0.176 1.29*10−4 0.165
Model 1 4.05*10−6 0.189 7.57*10−6 0.181
Model 2 7.47*10−5 0.170 1.15*10−4 0.163
hsa-miR-642a-5p
Correlation 7.80*10−5 0.170 2.63*10−4 0.157
Model 1 7.20*10−6 0.184 1.91*10−5 0.173
Model 2 2.49*10−6 0.192 5.58*10−6 0.183
hsa-miR-454-5p
Correlation 2.42*10−4 −0.174 1.34*10−4 −0.181
Model 1 1.54*10−4 −0.170 9.94*10−5 −0.171
Model 2 2.23*10−4 −0.165 1.40*10−4 −0.167
In individuals with IFG
hsa-miR-885-5p
Correlation 9.00*10−5 0.244 0.038 0.131 0.029 0.138
Model 1 0.007 0.169 0.010 0.135 0.007 0.142
Model 2 0.008 0.167 0.007 0.141 0.005 0.146
hsa-miR-106b-5p
Correlation 9.20*10−5 0.244 0.048 0.124 0.036 0.132
Model 1 2.82*10−4 0.223 0.041 −0.127 0.043 −0.125
Model 2 2.09*10−4 0.230
hsa-miR-122-5p
Correlation 8.42*10−7 0.334 9.31*10−7 0.333
Model 1 2.81*10−4 0.206 3.00*10−4 0.206
Model 2 1.76*10−4 0.207 2.05*10−4 0.206
hsa-miR-146b-5p
Correlation 4.90*10−5 0.254 6.30*10−5 0.250
Model 1 2.56*10−5 0.260 4.41*10−5 0.252
Model 2 6.05*10−5 0.251 5.25*10−5 0.252
Table 3. Significant (pc < 0.05) associations between miRNAs and serum glucose and insulin levels, the 
HOMA2 insulin resistance index, and glycated hemoglobin (HbA1c) levels and percentage in normoglycemic 
individuals and prediabetics separately. Associations are evaluated with Spearman’s correlation and stepwise 
regression models. *Multiply sign. Only p-values smaller than 0.05 are shown here, and those with a pc < 0.05 
are indicated by bold font. All p-values, numbers of samples, and 95%CIs are shown in Supplementary 
Tables 4 and 5. Statistical model: Correlation = Spearman’s correlation; Model 1 = Stepwise regression model 
including miRNA of interest (one by one), age, sex, and BMI; Model 2 = Model 1 + leukocyte, erythrocyte, and 
thrombocyte count, in addition to total cholesterol, LDL, HDL, and triglyceride levels, as well as glycemic status, 
alcohol consumption, and history of smoking or hypertension.
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When repeating the non-parametric tests and correlation in the serum samples (n = 146) of YFS, only 
results regarding hsa-miR-122-5p were replicated, indicating that the levels of this miRNA originate solely from 
serum. Hsa-miR-184, -589-3p, and 18-a-3p were not sufficiently expressed in serum samples to be included in 
the analysis, and the rest of the miRNAs of interest did not show an association with glycemic status groups 
or indicators of glucose metabolism in serum. With hsa-miR-122-5p, the FC between the IFG and NG groups 
is substantially greater in serum samples (FC = 1.75, p = 0.025) (Supplementary Fig. S2) in comparison to 
whole blood (FC = 1.14, p = 0.006), indicating that the presence of various other blood components in vary-
ing amounts does contribute noise to the measurements. In line with these results, also the correlation coeffi-
cients between hsa-miR-122-5p and glucose, insulin, and HOMA2-IR were greater in serum samples (r = 0.353, 
p = 2.36*10−5; r = 0.412, p = 5.54*10−7 and r = 0.419, p = 3.56*10−7, respectively) in comparison to blood sam-
ples (Supplementary Table S8).
Targets of hsa-miR-221-3p are enriched in pathways important to the development of T2D, 
while targets of hsa-miR-146b-5p are enriched in inflammatory pathways. The number of pre-
dicted targets with a correlation with a miRNA of interest varied greatly between the miRNAs (Supplementary 
File II, Correlation Tables 1–13). A correlation with a pc < 0.05 were only seen with miRNAs whose levels dif-
fered significantly between the glycemic status groups (let-7a-5p and hsa-miR-589-3p) or those with a significant 
association with HbA1c and HbA1c% (hsa-miR-93-3p, -146b-5p, -148a-3p, -221-3p and -642a-5p). The greatest 
number of associations were found between hsa-miR-221-3p (111 correlations with pc < 0.05) and hsa-miR-
146b-5p (42 correlations with pc < 0.05) and their targets. These were also the only miRNAs whose predicted 
targets were enriched in KEGG pathways (FDR q-value < 0.05) (Table 4). The insulin signaling pathway and Type 
2 diabetes mellitus pathways were most significantly enriched by the targets of hsa-miR-221-3p and were selected 
for closer investigation. In addition, we could see enrichment of hsa-miR-146b-3p targets in inflammatory path-
ways and a pathway related to the cytoskeleton.
MicroRNAs that associate with HbA1c levels are associated with the levels of genes in the insu-
lin signaling and T2D pathway. To assess the possible co-regulation of the miRNAs of interest in the insu-
lin signaling pathway and Type 2 diabetes signaling pathway we correlated the genes in these pathways with the 
miRNAs that were predicted to target them. Our results show that the HbA1c-associated miR-181a-2-3p, -146b-
5p, -148a-3p, and -221-3p, and hsa-let-7a and miR-589-3p, were also independently and significantly (p < 0.05) 
associated with mRNA levels of the insulin signaling pathway and type 2 diabetes pathway genes (Fig. 2A,B, 
Supplementary Tables S6 and S7). Most interestingly, hsa-miR-146b-5p correlated highly significantly and nega-
tively with 5′-AMP-activated protein kinase subunit gamma-2 (PRKAG2) mRNA levels, indicating the possible 
repression of mRNA target. We could also see a similar association between hsa-miR-221-3p and protein phos-
phatase 1 catalytic subunit beta (PPP1CB) and ribosomal protein S6 kinase B1 (RPS6KB1).
Description
Genes in 
pathway
Genes in 
overlap p-value
FDR 
q-value
Hsa-miR-221-3p
Insulin signaling pathway 137 8 6.60*10−5 0.006
Type II diabetes mellitus 47 5 9.63*10−5 0.006
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 25 4 9.75*10−5 0.006
Alzheimer’s disease 169 8 2.81*10–4 0.012
Cysteine and methionine metabolism 34 4 3.33*10−4 0.012
Tight junction 134 7 3.72*10−4 0.012
Purine metabolism 159 7 0.001 0.027
Spliceosome 128 6 0.002 0.039
Hsa-miR-146b-5p
Toll-like receptor signaling pathway 102 6 1.04*10−4 0.017
Adherens junction 75 5 2.21*10−4 0.017
Peroxisome 78 5 2.65*10−4 0.017
Regulation of actin cytoskeleton 216 7 0.001 0.045
Epithelial cell signaling in Helicobacter pylori infection 68 4 0.002 0.045
Pancreatic cancer 70 4 0.002 0.045
Leishmania infection 72 4 0.002 0.045
Lysosome 121 5 0.002 0.045
Endocytosis 183 6 0.002 0.046
Spliceosome 128 5 0.002 0.046
Table 4. Pathways enriched with the predicted targets of the miRNAs of interest. Only targets that were 
predicted by two algorithms and whose expression levels correlated with miRNA levels (p < 0.05) were included 
in the enrichment analysis. Significant results (FDR q-value < 0.05) were found only with hsa-miR-221-2p and 
-146b-5p. Abbreviations: FDR = false discovery rate. *Multiply sign.
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Figure 2. Association between miRNAs of interest and their predicted targets in the insulin signaling pathway 
(A) and Type II diabetes mellitus pathway (B)52. Transcripts whose expression correlated significantly (p < 0.05) 
with the miRNAs of interest and whose levels were independently and significantly associated with the targeting 
miRNA in the fully adjusted regression model* are marked with grey boxes. MicroRNAs whose expression 
correlated positively with glucose/insulin/HbA1c are indicated in red, while those with a negative correlation or 
down-regulation in individuals with IFG in comparison to NG are indicated in blue. Positive correlation 
between miRNA and its target mRNA is marked with  and negative correlation with . *Statistical model: 
Stepwise AIC linear regression model including the miRNA of interest, age, sex, BMI, leukocyte count, 
erythrocyte count, thrombocyte count, glycemic status, glucose insulin, as well as HbA1c levels, HbA1c%, and 
HOMA2 IR index statistically predicting the mRNA target.
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Discussion
T2D is a complex and heterogenic multi-organ disease, which is preceded by a state of increased blood glucose 
and the development of insulin resistance. We show here, in a general-population-based cohort, that IFG changes 
are associated with the miRNA expression in whole blood and that elevated levels of serum glucose, insulin, and 
glycated hemoglobin are strongly associated with the miRNA levels. Gene expression data from the same individ-
uals indicates that miRNAs whose expression is associated with HbA1c may also regulate the expression of their 
targets in the insulin signaling and type 2 diabetes mellitus pathway.
In YFS, the blood levels of hsa-miR-144-5p and hsa-let-7a-5p were down-regulated in individuals with pre-
diabetes. We have previously reported a negative correlation between whole blood hsa-miR-144-5p and serum 
glucose levels in a pilot population of YFS20 and now show herein that this miRNA is associated with (with 
negative β value) serum glucose, insulin, and HOMA2 index levels in the fully adjusted model. In contrast to 
our results, miR-144-5p has been previously reported to be up-regulated in the blood and blood fractions of 
diabetics21–23. In the regulation of glucose homeostasis, hsa-miR-144-5p has been shown to directly target Insulin 
receptor substrate 1 (IRS1)23 and Glucose transporter GLUT124 and thus regulate glucose metabolism on many 
levels. In our whole blood samples, we saw a strong association between hsa-miR-144-5p and serum triglyceride 
levels, possibly indicating that this miRNA may be connected to the development of T2D also through a role in 
fatty acid homeostasis, but no significant correlation with target mRNAs was observed. Hsa-let-7a-5p has also 
been associated with T2D. Its levels in exosomes have been shown to be decreased in individuals with T2D, 
and, interestingly, the levels increased after 12 months of diabetic medication25. In our transcriptomic analysis, 
hsa-let-7a-5p levels were associated with the levels of its predicted targets in pathways leading to glycolysis and 
mitochondrial dysfunction.
Hsa-miR-122-5p was significantly up-regulated in individuals with T2D, and the levels of this miRNA also 
correlated positively with insulin levels and the HOMA2-IR index in both the whole population and individuals 
with IFG. We and others have shown that the circulatory levels of this miRNA are up-regulated in whole blood 
and the blood fractions when fatty liver develops26,27. As up to 90% of diabetic individuals have some degree of 
fatty liver, it is reasonable to assume that the increase in this miRNA in our population reflects the development of 
fatty liver concomitantly with the dysregulation of glucose homeostasis. Although the levels of hsa-miR-122-5p 
have been measured from the whole blood samples of the larger YFS population, our results from the serum of 
the subpopulation of YFS participants indicates that the signal mainly comes from the serum. Hsa-miR-885-5p 
levels were also shown to be up-regulated in individuals with fatty liver in the YFS26, and in the IFG subpopu-
lation we can see that this miRNA also positively correlates with glucose levels, indicating a similar expression 
pattern to that of hsa-miR-122-5p.
Levels of hsa-miR-589-3p, a miRNA up-regulated in the whole blood of individuals with T2D, also correlated 
negatively with HbA1c levels in NG individuals. In the T2D populations, the correlation was positive, although 
it was not significant enough to survive the multiple testing correction and no correlation was seen in the IFG 
population. In our transcriptomics analysis, hsa-miR-589-3p levels correlated positively with transcripts inhib-
iting glycogenesis in the type 2 diabetes pathway. This may partly explain the complicated expression pattern of 
hsa-miR-589-3p in our population, as high blood glucose activates glycogenesis in individuals with a functional 
regulation of glucose levels, while defective glycogenesis is involved in the worsening of glucose level regulation 
in T2D28.
Hsa-miR-184 blood levels correlated negatively with insulin and HOMA2-IR index. This miRNA has been 
previously shown to be pancreas-enriched, and its expression has been shown to correlate negatively with 
glucose-stimulated insulin secretion29. It has been shown to regulate insulin secretion in a cell culture model30 
and in the compensatory β-cell proliferation and secretion during insulin resistance in mice31. The expres-
sion of hsa-miR-184 has been shown to be increased in the pancreatic islets of mice after fasting and to be 
down-regulated after the administration of a sucrose rich diet in drosophila31. No previous report exists on the 
correlation between circulatory levels of hsa-miR-184 and serum insulin levels, but our results indicate that the 
pancreatic down-regulation of this miRNA in the development of peripheral insulin resistance and the require-
ment of increased levels of insulin can also be seen in whole blood. In addition to hsa-miR-184, hsa-miR-339-3p 
levels correlated with insulin levels and the HOMA2-IR index. This miRNA has also been associated with the 
development of pancreatic islets32 and it has been reported to regulate the expression of glucose-6-phospahatse, 
the enzyme catalyzing the final steps of gluconeogenesis and glycogenolysis33, suggesting potential participation 
in the development of insulin resistance.
A total of eight miRNAs correlated with HbA1c levels/percentages and had an independent association in 
the fully adjusted model in the whole population. In addition, hsa-miR-454-5p had an association with HbA1c% 
in the NG subpopulation. Out of the combined nine miRNAs, miR-148a16 and -181a34 have been shown to be 
up-regulated in plasma and serum miR-15b35 and -18a36 to be down-regulated in T2D, while plasma miR-9315 and 
-148a16 have been shown to be down-regulated in prediabetics in comparison to healthy controls (Supplementary 
Table S9). Similar patterns of up-regulation of serum miR-148a and -181a37 and down-regulation of miR-9338 in 
PBMCs have been reported in type 1 diabetes. The associations between these miRNAs and HbA1c levels/per-
centages are well in line with their previously reported directions of regulation in T2D and prediabetes. Several 
of these miRNAs (miR-14839, -9340 and -14641) have been associated with obesity or/and the differentiation or 
phenotype of the adipocytes. In addition, miR-221 and -146 are known to be associated with inflammation42, 
and we were able to show that hsa-miR-146b-5p levels correlated with the leucocyte count, indicating that, in our 
samples, this miRNA may originate from inflammatory cells. In addition, in our data the predicted target mRNAs 
of hsa-miR-146b-5p were enriched in several inflammatory pathways—for example, the Toll-like receptor sign-
aling pathway. Interestingly, miR-15b has been shown to be down-regulated in the skeletal muscles of twins with 
T2D in comparison to those without T2D43, to suppress pancreatic β-cell proliferation and insulin secretion, and 
to possibly convey the effects of intrauterine conditions into later life in mice44.
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We detected a negative association between hsa-miR-93-3p and HbA1c levels. The expression of this miRNA 
has been shown to be down-regulated by high glucose in podocytes45 and in the plasma of prediabetic individu-
als46. It has also been shown to regulate the expression of Glucose transporter type 4 (GLUT4), the main glucose 
transporter in peripheral tissues, and of vascular endothelial growth factor (VEGF), which has an important role 
in the microvascular complications of diabetes; but it has also been shown to have a role in atherosclerosis. In 
addition, hsa-miR-221-3p, which associated with HbA1c levels, has been shown to be regulated by glucose levels, 
to mediate endothelial dysfunction47,48, and to be elevated in the internal thoracic arteries of individuals with T2D, 
but these levels were normalized by the usage of Metformin49. The predicted targets of this inflammation-related 
miRNA42 were seen to be enriched in the insulin signaling and type II diabetes mellitus pathways. Most interest-
ingly, a negative correlation was seen between hsa-miR-221-3p levels and levels of RPS6KB1 (p70S6K), which has 
been associated with insulin sensitivity, aging, and obesity, and serine/threonine-protein phosphatase PP1-beta 
catalytic subunit levels, which are known to participate in glycogen metabolism. Hsa-miR-221-3p levels also 
significantly correlated with the thrombocyte count, suggesting a possible cell type of origin. Our results thus 
indicate that hsa-miR-93-3p and -221-3p could mediate the effects of elevated blood glucose to the vascular 
endothelial cells.
When analyzing the co-regulation of the miRNAs of interest in the insulin signaling pathway and Type 2 
diabetes mellitus pathway, we were able to see a significant correlation between hsa-miR-146-5p and its predicted 
target PRKAG2, a part of the AMP-activated protein kinase and a major cellular regulator of lipid and glucose 
metabolism. Hsa-miR-181a-2-3p levels, on the other hand, correlated negatively with genes leading to the trans-
port of GLUT4 to the plasma membrane in the insulin signaling pathway, while it seemed to activate the route 
leading to insulin resistance in the type II diabetes mellitus pathway. Transcriptomic analysis also showed a sig-
nificant association between miR-148a and its predicted target heksokinase 1, the enzyme catalyzing the first step 
of glycolysis, which has previously been shown to also be associated with the levels of HbA1c50.
A limitation of our study is that profiling miRNAs from blood poses a challenge for identifying the origin of 
the miRNAs, as blood contains miRNAs from circulatory cells but also circulatory miRNA originating from var-
ious tissues26. As the whole blood levels can be affected by the amount of exportation from surrounding tissues, 
but also by the changes in in expression in circulatory cells, the whole blood miRNA levels are not necessarily 
representative of the miRNA levels in tissues important to development of T2D, such as the pancreas or skeletal 
muscle. Our results with hsa-miR-122-5p do indicate that, if the miRNA levels originate solely from serum, ana-
lyzing the miRNA levels from whole blood increases the noise in the measurement and reduces the magnitude of 
the FCs and correlation coefficients. Whole blood was selected to enable gene-expression analysis from the same 
sample26. As almost all of the mRNAs quantified from whole blood originate from circulatory blood cells, our 
target analysis mainly represents gene expression regulation in hematopoietic cells and may not fully describe 
the processes in other tissues important to T2D. Oral glucose tolerance tests had not been performed for the 
study population, and hence we are unable to reflect upon the association between blood miRNA profiles and 
impaired glucose tolerance. In addition, replication in other populations is needed to verify the findings. The YFS 
population is still rather young and just approaching the age where T2D is most frequently diagnosed. Because 
of this, we can provide information about the miRNAs’ associations with physiological glucose levels, but as the 
number of individuals with T2D is low, further analysis is needed to connect the discovered miRNAs to the onset 
of T2D. The strengths of this study are the large, well-phenotyped population-based cohort and the availability of 
genome-wide gene expression data from the same samples, which enables detailed analysis of specific biological 
processes through which miRNAs may exert their effects. As this work is essentially descriptive, more research is 
needed to shed light on the mechanism of how miRNAs are released into the blood and to validate the interaction 
of the discovered miRNAs and their targets26. In addition, as T2D is a heterogenous disease with different pro-
gression patters, it is possible that known and unknown cofactors are affecting our results.
In conclusion, we are able to show that, in a population-based study cohort, glycemic status and blood glu-
cose/insulin/HbA1c levels are associated with the miRNA expression profile in whole blood. These associations 
are well in line with previous results from peripheral tissues and the pancreas during the development of T2D. 
There were also significant differences in the blood miRNA profiles associating with serum glucose, insulin, or IR 
levels when compared to those associating with HbA1c. As the HbA1c-associated miRNAs were strongly associ-
ated with the gene expression of the target mRNAs in insulin signaling and type II diabetes mellitus pathways, it 
can be hypothesized that long-term glucose levels in particular can affect gene expression via miRNA regulation.
Methods
See the full research design and methods information in the supplementary materials. The 
Young Finns Study (YFS). YFS is a multi-center follow-up study on cardiovascular risk from childhood to adult-
hood in Finland. The YFS was launched in 1980, with 3,596 children and adolescents randomly selected from the 
Finnish national population register. The 30-year follow-up was performed in 2011, with 2,063 adults aged 34–49 
years participating in the study. The examinations included physical measurements, blood tests, and question-
naires51. The present study has been approved by the 1st ethical committee of the Hospital District of Southwest 
Finland on September 21st, 2010 and by local ethical committees. All study subjects gave an informed consent, 
and the study was conducted according to the principles of the Declaration of Helsinki. As previously described26, 
the YFS samples for miRNA analysis (n = 992) were selected independently of glycemic status from individuals 
with the most comprehensive data. After quality control, the study population comprises 871 individuals with 
successful miRNA profiling (Table 5).
Clinical and biochemical measurements. As previously described26, weight, height, waist circumference, and 
blood pressure were measured, and body mass index (BMI) was calculated. Blood cell parameters were measured 
with flow cytometric particle counting and photometry. The serum triglyceride, glucose, and total cholesterol 
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concentrations were analyzed using the enzymatic methods. HDL cholesterol levels were estimated after the pre-
cipitation of low-density lipoprotein (LDL) and very-low-density lipoprotein. For HbA1c fraction measurement, 
the concentration of total hemoglobin was determined colorimetrically, after which the concentration of HbA1c 
was measured immunoturbidimetrically. These two concentrations were used to calculate the HbA1c percent-
age (HbA1c%). Insulin levels were measured by a microparticle enzyme immunoassay kit, and the HOMA2 
index was calculated according to the online HOMA2-IR calculator (https://www.dtu.ox.ac.uk/homacalculator/). 
Individuals were categorized into the normoglycemic (NG), IFG, and T2D groups. The classification of IFG was 
based on fasting serum glucose and HbA1c according to the criteria of the WHO3. Individuals with type 1 diabe-
tes were discarded from the analysis.
Whole blood RNA isolation and miRNA expression profiling. The sample collection and miRNA profiling has 
been described previously26. In brief, whole blood was collected into PaXgene Blood RNA Tubes and RNA iso-
lated with a PAXgene Blood MicroRNA Kit. MicroRNA expression profiling was performed with the TaqMan® 
OpenArray® MicroRNA Panel containing 758 microRNAs. Primary data analysis was performed with Expression 
Suite Software version 1.0.1. RNU6, RNU44, and RNU48 were used as housekeeping small RNAs. Two hundred 
and forty-three (243) miRNAs that were expressed in at least 2/3 of the samples were included in the analysis. The 
RNA quality and functionality of the panels has been validated previously20. Profiling was successful in 871 sam-
ples. To correct for batch effects, the principal component analysis was performed for the miRNA expression data.
Genome-wide expression analysis (transcriptomics). The expression levels were analyzed with an Illumina 
HumanHT-12 version 4 Expression BeadChip26. Raw Illumina probe data was exported from Genomestudio 
and analyzed in R using the Bioconductor packages. The expression data was processed using nonparametric 
background correction, followed by quantile normalization with control and expression probes. The expression 
analysis was successful in 743 of the 871 samples with a miRNA expression profile.
Statistical analysis. MicroRNA expression differences over glycemic status groups were analyzed with 
Kruskal-Wallis analysis of variance, and the different glycemic status groups were then compared by using the 
Mann-Whitney U test. Bonferroni-corrected p-values (pc-value = nominal p-value/243) were calculated, and a 
pc-value of <0.05 (=p < 0.00021) was considered significant. For dysregulated miRNAs, fold changes (FCs) were 
calculated for each individual sample in comparison to the median of all NG individuals. To analyze whether 
dysregulated miRNAs were independent statistical predictors of IFG or T2D, a stepwise Akaike information 
All* NG IFG T2D
Number of subjects 871 534 252 24
Age, years 43 (4.8) 41.9 (4.9) 43.2 (4.7) 45.1 (3.5)
Males, (%) 45.4 38.8 59.9 54.2
Total cholesterol, mmol/l 5.1 (0.9) 5.1 (0.9) 5.3 (0.9) 5.0 (0.9)
HDL cholesterol, mmol/l 1.3 (0.4) 1.4 (0.3) 1.3 (0.3) 1.2 (0.4)
LDL cholesterol, mmol/l 3.2 (0.8) 3.2 (0.8) 3.4 (0.9) 3.0 (0.8)
Triglycerides, mmol/l 1.1 (0.7) 1.1 (0.7) 1.4 (0.7) 1.8 (0.9)
Medication for hypercholesterolemia (%) 3.4 1.9 4.8 12.5
Blood glucose, mmol/l 5.3 (0.9) 5.1 (0.3) 5.7 (0.5) 7.0 (1.8)
HbA1c, %, 5.4 (0.4) 5.4 (0.2) 5.6 (0.3) 6.6 (1.0)
HbA1c, mmol/mol 36.0 (4.6) 25.2.0) 38.1 (3.0) 48.1 (11.3)
Insulin, mU/l 9.9 (15.4) 7.0 (4.9) 11.4 (8.8) 19.4 (14.6)
HOMA2 IR 1.1 (2.1) 0.9 (0.6) 1.5 (1.1) 2.6 (2.0)
Oral diabetes medication (%) 1.0 0 0.4 33.3
Insulin medication (%) 0.3 0 1.2 0
Hypertension, (%) 8.2 5.2 11.1 37.5
Systolic, mmHg 117.7 (13.9) 116.3 123.7 (13.5) 126.1 (17.8)
Diastolic, mmHg 74.2 (10.5) 73.0 (10.0) 78.4 (10.2) 79.0 (9.1)
Medication for hypertension (%) 9.0 5.8 12.3 33.3
Body mass index, kg/m2 25.6 (4.9) 25.3 (3.9) 28.2 (5.5) 30.7 (6.7)
Fatty liver, (%) 3.2 0.9 5.6 20.8
Mild fatty liver, (%) 13.7 7.5 21.4 41.7
Leukocyte count, 109/l 5.5 (1.5) 5.3 (1.3) 5.7 (1.5) 6.4 (2.2)
Erythrocyte count, 1012/l 4.7 (0.4) 4.6 (0.4) 4.8 (0.4) 4.7 (0.4)
Thrombocyte count, 109/l 256.2 (58.1) 252.9 (58.9) 260 (52.8) 279.0 (54.9)
Table 5. Demographics of the Young Finns Study participants with successful miRNA profiling. Continuous 
variables are presented by means, with standard deviations in parentheses. *Individuals with type 1 diabetes or 
lacking information on blood glucose levels and/or HbA1c levels are not included in the groups determined by 
glycogenic status.
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criterion (AIC) logistic regression model was utilized. Two different models were used as follows: Model 1: The 
dependent variable was glycemic status as statistically predicted with the discovered miRNAs, age, sex, and BMI; 
and Model 2: Model 1 + leukocyte, erythrocyte, thrombocyte count, total cholesterol, LDL, HDL, and triglycer-
ide levels, as well as alcohol consumption and history of smoking and hypertension. In the regression models, all 
continuous variables were inverse-normalized. The number of samples in the regression models varies according 
to the number of samples in which the miRNA was expressed and according to the availability of the variables in 
the regression models, as all measurements were not successful/available from all of the samples.
The associations between miRNA levels and glucose, insulin, HbA1c, HbA1c%, and HOMA2 IR index were 
correlated with Spearman’s rank-order correlation. Pc-value < 0.05 was considered significant. The independent 
statistical prediction value was evaluated with AIC linear regression models with the same covariates as in the 
logistic regression models (Model 1 and Model 2), but with glycemic status also included in Model 2. Analyses 
stratified by glycemic status were performed as in the whole population, without glycemic status as a cofactor in 
Model 2. In regression models, p < 0.05 was considered significant.
To analyze the co-regulation of the miRNAs of interest and the existence of possible expression clusters of 
these miRNAs, between-miRNA Spearman’s rank-order correlations were analyzed. Also, to validate our results, 
we analyzed the differences in hsa-miR-144-5p and -let-7a-5p over the glycemic status groups with miRNA data 
profiled with Human MiRNA Microarray Release 14.0, 8 × 15 K (Agilent) from the whole blood of 72 individu-
als from the YFS 2011 follow-up. The sample preparation, miRNA profiling, and data preprocessing have been 
described previously20. Differences in microRNA expressions between glycemic status groups were analyzed, 
as with the larger data set, from whole blood, and hsa-miR-144-5p and -let-7a were selected because they were 
available for both arrays and gave significant results in the non-parametric tests.
To analyze the possibility that miRNAs associated with the individuals’ glycemic status, glucose levels, or indi-
cators of insulin resistance are expressed particularly in certain circulatory blood cells, we correlated the levels 
of these miRNAs with the leukocyte, erythrocyte, and thrombocyte counts by means of Spearman’s rank-order 
correlation. In addition, we investigated whether some of the miRNAs were originating solely from serum by 
replicating the non-parametric tests, and the correlation between the miRNAs of interest and glycemic status, and 
the indicators of glucose metabolism in the serum miRNA profilings was performed with TaqMan® OpenArray® 
MicroRNA Panels from a subpopulation (n = 146) of the YFS (see supplementary materials and methods).
In the target mRNA analysis, Spearman’s rank-order correlations were performed between the FCs of the miR-
NAs of interest (miRNAs with significantly different levels between glycemic status groups or significant correla-
tion with glucose, insulin, HbA1c, HbA1c% levels, or HOMA2 index in the whole population) and the expression 
of their predicted targets (predicted by two or more algorithms according to miRGator v.3.0, http://mirgator.
kobic.re.kr/). Transcripts with a correlation p < 0.05 were included in a pathway enrichment analysis performed 
for the KEGG pathways in the molecular signatures database (http://software.broadinstitute.org/gsea/msigdb/
index.jsp). Pathways with an FDR-q value of <0.05 were considered significantly enriched with target mRNAs. 
The most significant pathways were further analyzed for the coregulation of all of the miRNAs of interest. All 
predicted targets (predicted by at least one algorithm in miRGator 3.0) from at least one of the miRNAs of interest 
were selected from the most significantly enriched pathways and correlated (Spearman’s rank-order correlation) 
with their predicted regulatory miRNA levels. The predicted target mRNAs with significant correlation (p < 0.05) 
were included in further analysis. The independent statistical prediction values of the miRNAs of interest on the 
levels of target mRNA were evaluated with an AIC linear regression model including the miRNA of interest, age, 
sex, BMI, leukocyte count, erythrocyte count, thrombocyte count, glycemic status, as well as the glucose, insulin, 
and HbA1c levels, and HbA1c% and HOMA2 IR index. Transcripts whose levels were significantly (p < 0.05) 
and independently statistically predicted by the levels of the miRNAs of interest were considered to be affected 
by these miRNAs.
perspectives. As the prevalence of type 2 diabetes increases, it is crucial to understand the underlying molec-
ular mechanisms. We found that there were significant differences in the blood microRNA profiles associated 
with serum glucose, insulin levels, or insulin resistance index compared to those associated with HbA1c. The 
HbA1c-associated miRNAs were strong statistical predictors of the expression of target mRNAs in pathways 
important to the development of T2D, highlighting the role of microRNAs in regulating pathways during T2D 
pathogenesis.
Data Availability
The data sets generated and/or analyzed during the current study are not publicly available due to restrictions 
imposed by Finnish legislation but are available from the corresponding author upon a reasonable request.
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